Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Phase I/II Trial Of Tremelimumab In Patients With Metastatic Melanoma.

L. Camacho, S. Antonia, J. Sosman, J. Kirkwood, T. Gajewski, B. Redman, D. Pavlov, C. Bulanhagui, V. Bozon, J. Gomez-Navarro, A. Ribas
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with tremelimumab (CP-675,206), a fully human anti-CTLA4 monoclonal antibody, was tolerated and demonstrated antitumor activity in a single dose, dose-escalation phase I trial in patients with solid tumors. This phase I/II trial was conducted to examine safety of multiple doses of tremelimumab, to further assess efficacy, and to identify an appropriate dosing regimen for further development. PATIENTS AND METHODS Twenty-eight patients with metastatic melanoma received monthly intravenous infusions of tremelimumab at 3, 6, or 10 mg/kg for up to 1 year to determine recommended monthly phase II dose. During phase II, 89 patients received tremelimumab 10 mg/kg once every month or 15 mg/kg every 3 months. RESULTS No dose-limiting toxicity was observed in phase I once every month dosing. In phase II, 8 (10%) of 84 response-assessable patients attained objective antitumor responses; best overall objective response was one complete response and three partial responses in each dosing regimen. Most responses were durable (range, 3 to 30+ months). Most frequent treatment-related adverse events (AEs) were diarrhea, rash, and pruritus. Frequency of grade 3/4 AEs was 13% in the 15 mg/kg every 3 months arm and 27% in the 10 mg/kg once every month. Serious AEs were also less frequent in the 15 mg/kg once every 3 months cohort (9% v 23% in 10 mg/kg arm). CONCLUSION Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. Both phase II regimens generated durable tumor responses. Based on its more favorable safety profile, 15 mg/kg every 3 months was selected for further clinical testing.
This paper references
10.1158/1078-0432.CCR-06-2318
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
E. Small (2007)
10.1200/JCO.2004.22.14_SUPPL.7511
A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma.
E. Hersh (2004)
10.1200/JCO.2004.22.90140.709
Evaluation of routine radiation boost following breast conservation therapy in young patient
J. Lamont (2004)
10.1002/cncr.22427
Chemotherapy for metastatic melanoma
H. Gogas (2007)
Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha Ss (1997)
10.1146/ANNUREV.IMMUNOL.14.1.233
CD28/B7 system of T cell costimulation.
D. Lenschow (1996)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1517/13543784.17.3.371
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
L. Camacho (2008)
10.1517/14728222.11.4.497
Targeting Nodal in malignant melanoma cells
L. Postovit (2007)
Expression and function of CTLA-4 in Th1 and Th2 cells.
M. Alegre (1998)
10.1002/14651858.CD005413.PUB2
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
A. Sasse (2007)
10.1200/JCO.2007.14.6423
Next generation of immunotherapy for melanoma.
J. Kirkwood (2008)
10.1634/THEONCOLOGIST.12-7-864
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
10.1200/JCO.2008.26.15_SUPPL.LBA9011
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
10.1200/JCO.2004.22.14_SUPPL.7505
Randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival.
MichaelJ. Millward (2004)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1186/1471-2407-6-44
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
V. Chiarion-Sileni (2005)
10.1634/THEONCOLOGIST.12-9-1084
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
S. Strome (2007)
10.1073/PNAS.220423597
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells.
M. S. Kuhns (2000)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1200/JCO.1999.17.9.2745
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
P. Chapman (1999)
10.1200/JCO.2008.26.15_SUPPL.9023
A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
J. Kirkwood (2008)
10.2108/zsj.17.1107
Expression and Function of Xmsx-2B in Dorso-Ventral Axis Formation in Gastrula Embryos
I. Onitsuka (2000)
10.1200/JCO.2004.22.14_SUPPL.708
Integration of intra-operative electron irradiation (IOERT) in breast conserving treatment for T1/T2N0 breast cancer: Early results of a phase II tria.
W. Wong (2004)
10.1200/JCO.2007.25.18_SUPPL.8524
Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study
J. Gomez-Navarro (2007)
10.1200/JCO.2008.26.15_SUPPL.3040
Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer
N. Wallis (2008)
10.1186/1479-5876-6-22
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
B. Comin-Anduix (2008)
10.1200/JCO.2005.01.109
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
10.1200/JCO.2007.12.7837
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)



This paper is referenced by
10.1080/2162402X.2018.1468956
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
D. Bajor (2018)
10.1371/journal.pone.0022303
Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
J. Persson (2011)
10.1097/MD.0000000000003997
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
F. Petrelli (2016)
10.1002/9781118345313.CH25
Co‐Administration of Co‐Stimulatory Moieties
Y. Latchman (2012)
10.1200/JCO.2013.50.2120
Reply to K.S. Wilson et al.
A. Ribas (2013)
10.1101/176768
The antibody repertoire of colorectal cancer
S. W. Cha (2017)
10.1002/cncr.24951
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
10.1097/PPO.0b013e3181eb3393
Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma
A. Shada (2010)
10.1371/journal.pone.0012711
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
B. Comin-Anduix (2010)
10.1097/PPO.0b013e3181eb3381
Immune Regulatory Antibodies: Are They the Next Advance?
J. Wolchok (2010)
Ipilimumab Induced Enterocolitis: A Fatal Immune-Related Adverse Event of Melanoma Treatment
Chandamuri Babi (2013)
10.1111/j.1743-7563.2011.01383.x
CTLA‐4 to overcome immunological tolerance to melanoma
F. S. Hodi (2011)
10.1016/j.pharmthera.2018.12.003
Body composition and sarcopenia: The next‐generation of personalized oncology and pharmacology?
M. Hilmi (2019)
10.1097/CMR.0b013e32834710b5
High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy
A. Buzaid (2011)
10.1007/978-3-662-44946-2_6
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
G. Clifton (2015)
10.3389/fneur.2015.00033
Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response
Raymond Y Huang (2015)
10.1007/s00262-017-2007-x
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
U. Hegde (2017)
10.1155/2011/182413
The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring
M. Vergati (2011)
10.1021/bk-2012-1115.ch016
Improving the clinical efficacy of cancer vaccines by targeting immune suppression in human tumors
N. Demotte (2012)
10.1155/2011/894704
The Immune Response to Tumors as a Tool toward Immunotherapy
F. Pandolfi (2011)
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
A. Jazirehi (2016)
10.1007/s11060-015-1747-8
The role of checkpoints in the treatment of GBM
J. E. Kim (2015)
10.1016/j.clinthera.2015.02.003
Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Elizabeth I Buchbinder (2015)
10.1002/9781118684535.CH19
Interaction between Targeted Therapy and Immunotherapy
P. A. Prieto (2018)
10.1159/000490025
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
10.15406/MOJI.2016.03.00092
CTLA-4 Antibodies in Cancer Immunotherapy
Veerendra Koppolu (2016)
10.21007/ETD.CGHS.2017.0446
Discovery of Novel Tubulin Inhibitors and Selective Survivin Inhibitors for Advanced Melanoma and Total Synthesis of Bioactive 20S-hydroxyvitamin D3
Qinghui Wang (2017)
10.1159/000436998
Immunotherapy of Melanoma.
A. Snyder (2015)
10.1016/j.molonc.2011.01.004
Immunologic functions as prognostic indicators in melanoma
Marna G. Bouwhuis (2011)
10.1053/j.seminoncol.2010.09.009
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
A. Eggermont (2010)
10.1038/nrclinonc.2016.58
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros (2016)
10.1093/annonc/mdu205
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
M. Aglietta (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar